Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment  Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu.

Similar presentations


Presentation on theme: "Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment  Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu."— Presentation transcript:

1 Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment  Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu Notsu, Sayuri Tanaka, Nobuaki Kiyohara, Sayo Koike, Yuko Yamane, Yuko Tada, Motofumi Sasaki, Mika Yamauchi, Toshitsugu Sugimoto  Diabetes Research and Clinical Practice  Volume 123, Pages 9-17 (January 2017) DOI: /j.diabres Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

2 Fig. 1 Patient disposition.
Diabetes Research and Clinical Practice  , 9-17DOI: ( /j.diabres ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

3 Fig. 2 Unadjusted mean (±SE) changes in HbA1c. *p<0.05; **p<0.01; ***p<0.001 vs. baseline in each group. Diabetes Research and Clinical Practice  , 9-17DOI: ( /j.diabres ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

4 Fig. 3 Mean changes (±SE) in HbA1c from baseline to the last observation. **p<0.01 vs. control. Diabetes Research and Clinical Practice  , 9-17DOI: ( /j.diabres ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

5 Fig. 4 Adjusted mean changes (±SE) in dose (A) and number (B) of insulin injections from baseline ***p<0.001 vs. baseline in each group. Diabetes Research and Clinical Practice  , 9-17DOI: ( /j.diabres ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

6 Fig. 5 Mean changes (±SE) in dose and number of insulin injections from baseline to the last observation **p<0.01; ***p<0.001 vs. control. Diabetes Research and Clinical Practice  , 9-17DOI: ( /j.diabres ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

7 Fig. 6 Mean changes (±SE) in dose of total, bolus, and basal insulin from baseline to the last observation. *p<0.05; **p<0.01 vs. control. Diabetes Research and Clinical Practice  , 9-17DOI: ( /j.diabres ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions

8 Fig. 7 Adjusted mean change (±SE) in body weight (A), ALT (B), and eGFR (C) from baseline. Diabetes Research and Clinical Practice  , 9-17DOI: ( /j.diabres ) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions


Download ppt "Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment  Ippei Kanazawa, Ken-ichiro Tanaka, Masakazu."

Similar presentations


Ads by Google